Literature DB >> 9506239

Combination diuretic therapy in severe congestive heart failure.

T P Dormans1, P G Gerlag, F G Russel, P Smits.   

Abstract

Severe congestive heart failure (CHF) is often characterised by fluid retention. A (chronic) state of overhydration has a negative influence on both the quality of life and prognosis of these patients. Therefore, the use of diuretics remains a cornerstone in the treatment of heart failure. However, diuretic resistance, a failure to correct the hydration state adequately with the use of conventional dosages of loop diuretics, is a frequently occurring complication in the treatment of advanced stages of CHF. Several intra- and extrarenal mechanisms may be involved in the development of diuretic resistance. An important pathophysiological mechanism leading to diuretic resistance seen after chronic use of loop diuretics is the functional adaptation of the distal tubule. Studies in animals demonstrate that the sodium reabsorption capacity of this nephron segment increases significantly when the sodium delivery to this segment is augmented, as is the case during administration of loop diuretics. The use of combinations of diuretics acting on different segments of the nephron appears to be an effective option in the treatment of diuretic resistance. Several combinations have been used; however, the combination of a loop diuretic and a thiazide drug acting on the distal tubule appears to be the most effective. However, since the use of this combination may lead to serious adverse effects such as hypokalaemia, metabolic alkalosis and dehydration, careful monitoring of the patient of combination diuretic therapy is necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506239     DOI: 10.2165/00003495-199855020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  58 in total

1.  Mechanism of impaired natriuretic response to furosemide during prolonged therapy.

Authors:  N R Loon; C S Wilcox; R J Unwin
Journal:  Kidney Int       Date:  1989-10       Impact factor: 10.612

2.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.

Authors:  T P Dormans; J J van Meyel; P G Gerlag; Y Tan; F G Russel; P Smits
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

3.  The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology.

Authors: 
Journal:  Eur Heart J       Date:  1997-05       Impact factor: 29.983

Review 4.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance.

Authors:  D H Ellison
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

5.  Role of duration of diuretic effect in preventing sodium retention.

Authors:  J A Ferguson; K J Sundblad; P K Becker; J C Gorski; D W Rudy; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

6.  Increase in hospital admission rates for heart failure in The Netherlands, 1980-1993.

Authors:  J B Reitsma; A Mosterd; A J de Craen; R W Koster; F J van Capelle; D E Grobbee; J G Tijssen
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

7.  Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular fluid volume depletion.

Authors:  V Kon; A Yared; I Ichikawa
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

8.  Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance.

Authors:  J J van Meyel; P Smits; T Dormans; P G Gerlag; F G Russel; F W Gribnau
Journal:  J Intern Med       Date:  1994-04       Impact factor: 8.989

9.  Adaptation of distal convoluted tubule of rats. II. Effects of chronic thiazide infusion.

Authors:  P Morsing; H Velázquez; F S Wright; D H Ellison
Journal:  Am J Physiol       Date:  1991-07

10.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

Authors:  A A van Vliet; A J Donker; J J Nauta; F W Verheugt
Journal:  Am J Cardiol       Date:  1993-01-21       Impact factor: 2.778

View more
  8 in total

1.  Acute Heart Failure Treatment.

Authors:  Phillip D Levy; Abdel Bellou
Journal:  Curr Emerg Hosp Med Rep       Date:  2013-06-01

Review 2.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

Review 3.  The cardiorenal syndrome: lessons from the ADHERE database and treatment options.

Authors:  J Thomas Heywood
Journal:  Heart Fail Rev       Date:  2004-07       Impact factor: 4.214

4.  Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Authors:  Jacob K Meariman; Jane C Sutphen; Juan Gao; Daniel R Kapusta
Journal:  Hypertension       Date:  2021-12-02       Impact factor: 10.190

Review 5.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 6.  Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence.

Authors:  Cara Tannenbaum; Kristina Johnell
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923

Review 7.  Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review.

Authors:  Simge Acar; Sueda Sanli; Cinar Oztosun; Baris Afsar; Alan A Sag; Masanari Kuwabara; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

8.  Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.

Authors:  Salvatore Paterna; Francesca Di Gaudio; Vincenzo La Rocca; Fabio Balistreri; Massimiliano Greco; Daniele Torres; Umberto Lupo; Giuseppina Rizzo; Pietro di Pasquale; Sergio Indelicato; Francesco Cuttitta; Javed Butler; Gaspare Parrinello
Journal:  Adv Ther       Date:  2015-10-31       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.